Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Core Insights - Agios Pharmaceuticals announced that its sickle cell drug achieved one of its two primary objectives in a late-stage study involving patients aged 16 and older, but did not demonstrate a statistically significant reduction in the other primary endpoint [1] Group 1: Study Results - The drug met one of the two main goals in the late-stage study [1] - The study involved patients aged 16 and older [1] - The drug failed to show a statistically significant reduction in the second primary endpoint [1]